Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 145Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Neoplasm Metastasis 9Breast Neoplasms, Male 9Neoplasms 5Ovarian Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gliosarcoma 3Glioma 3Glioblastoma 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Ductal, Breast 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Oligodendroglioma 2Multiple Endocrine Neoplasia Type 1 2Liver Neoplasms 2Hot Flashes 2Glioma, Subependymal 2Fibroadenoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Astrocytoma 2Thyroid Neoplasms 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Tamoxifen 1Paclitaxel 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Breast Cancer × Tamoxifen × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡